Overview

Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy. A phase II multicenter and randomized placebo-controlled study

Phase:

Phase 2

Details

Lead Sponsor:

French Innovative Leukemia Organisation

Collaborator:

Novartis Pharmaceuticals